CTB Histone Acetyltransferase activator

Cat.No.E1107

CTB is a p300 activator and the lowest docked energy for this compound and p300 is 7.72 kcal/mol.
CTB Histone Acetyltransferase activator Chemical Structure

Chemical Structure

Molecular Weight: 343.73

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 343.73 Formula

C16H13ClF3NO2

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 451491-47-7 -- Storage of Stock Solutions

Solubility

In vitro
Batch:

DMSO : 69 mg/mL (200.73 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 17 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vitro

CTB effectively induces apoptosis, up-regulates the expression of P300, and increases the acetylation and total P53 protein levels in MCF-7 cells.[2]

In vivo

CTB combinated with CpG, and aluminum hydroxide playsa synergistic effect to enhance ClfA221-550-induced immune responses, which possesses the potential to develop a novel vaccine to prevent infection of S. aureus.[3]

References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05433181 Not yet recruiting
SARS-CoV-2
University of Pennsylvania
February 2025 Phase 1|Phase 2
NCT06344559 Not yet recruiting
Healthy
Rutgers The State University of New Jersey
May 1 2024 Not Applicable
NCT06347055 Not yet recruiting
Nicotine Dependence
University of Missouri-Columbia
April 15 2024 Not Applicable
NCT06301334 Not yet recruiting
Pain Mangement of Thoracotomy
Sohag University
March 1 2024 Not Applicable
NCT05646732 Recruiting
Post Traumatic Stress Disorder|PTSD
Allyson Rosen|National Institute of Mental Health (NIMH)|Palo Alto Veterans Institute for Research
August 2 2023 Not Applicable
NCT05983211 Recruiting
Amyotrophic Lateral Sclerosis
Sunnybrook Health Sciences Centre
June 1 2023 Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map